Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>In vivo</i> mechanisms of resistance to cytarabine in acute myeloid leukaemia

1 Jun 2002

Abstract excerpt

Factors that reduce the intracellular concentration of triphosphorylated cytarabine (ara-CTP), the active form of cytarabine (ara-C), may induce chemoresistance in acute myeloid leukaemia (AML) patients. These factors include reduced influx of ara-C by the hENT1 transporter, reduced phosphorylation by deoxycytidine kinase (dCK), and increased degradation by high Km cytoplasmic 5'-nucleotidase (5NT) and/or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12060121
DOI: 10.1046/j.1365-2141.2002.03538.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>In vivo</i> mechanisms of resistance to cytarabine in acute myeloid leukaemiaPMID 12060121Read ↗

RNA Expression of Genes Involved in Cytarabine Metabolism and Transport Predicts Cytarabine Response in Acute Myeloid LeukemiaSemantic proximity Read ↗

Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.Semantic proximity Read ↗

Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.Semantic proximity Read ↗

Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolismSemantic proximity Read ↗

Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.Semantic proximity Read ↗

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.Semantic proximity Read ↗

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cellsSemantic proximity Read ↗

Role of oncogenes in resistance and killing by cancer therapeutic agentsSemantic proximity Read ↗

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.Semantic proximity Read ↗

Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesSemantic proximity Read ↗

Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies TreatmentSemantic proximity Read ↗

Genetic factors influencing cytarabine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.